Veracyte's Q1 Revenue Surges 21% to $139.1M, Adjusted EPS Reaches $0.52
VCYT sits 68% above its 52-week low of $22.61.
Summary
Veracyte reported robust first-quarter 2026 financial results, with total revenue increasing 21% year-over-year to $139.1 million and testing revenue growing 26% to $135.1 million. The company achieved an adjusted diluted earnings per share of $0.52, alongside a strong adjusted EBITDA margin of 30.8%. This strong performance builds on the positive momentum from full-year 2025, driven by significant volume growth in its key Decipher and Afirma diagnostic tests, which saw revenue increases of 30% and 21% respectively. The impressive growth rates and profitability demonstrate strong demand for Veracyte's diagnostic portfolio and effective operational execution. Investors will be watching for continued growth in testing volumes, progress in ongoing clinical trials, and the successful commercialization of upcoming product launches like Prosigna LDT and TrueMRD.
At the time of this announcement, VCYT was trading at $38.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $22.61 to $50.71. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.